Sugi Predict
/ Targets
/ MAPK3
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MAPK3 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma |
PHASE4 | UNKNOWN |
| Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation |
PHASE4 | ACTIVE_NOT_RECRUITING |
| Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. |
PHASE3 | UNKNOWN |
| Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome |
PHASE3 | COMPLETED |
| Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer |
PHASE2 | COMPLETED |
| SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS |
PHASE2 | COMPLETED |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations |
PHASE2 | ACTIVE_NOT_RECRUITING |
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma |
PHASE1/PHASE2 | COMPLETED |
| Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer |
PHASE2 | COMPLETED |
| A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma |
PHASE1/PHASE2 | COMPLETED |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations |
PHASE2 | RECRUITING |
| To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. |
PHASE2 | UNKNOWN |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer |
PHASE2 | UNKNOWN |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
PHASE2 | COMPLETED |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
PHASE1 | COMPLETED |
| A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors |
PHASE1 | COMPLETED |
| BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) |
PHASE1 | COMPLETED |
| Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients |
PHASE1 | UNKNOWN |
| Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia |
PHASE1 | RECRUITING |
| A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 |
PHASE1 | COMPLETED |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
PHASE1 | COMPLETED |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
PHASE1 | COMPLETED |
| Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo |
nan | UNKNOWN |
| BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation |
nan | COMPLETED |
| BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients |
nan | COMPLETED |
| Muscle Wasting in Cancer (MWIC) |
nan | COMPLETED |
| Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma |
nan | COMPLETED |
| Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. |
nan | COMPLETED |
| Histiocytic Disorder Follow-up Study |
nan | RECRUITING |
| Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
nan | ACTIVE_NOT_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a MAPK3 binder may also engage these)